Skip to Content

Methohexital Pregnancy and Breastfeeding Warnings

Methohexital is also known as: Brevital Sodium

Methohexital Pregnancy Warnings

No adverse developmental effects were observed in animal studies. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk. US FDA pregnancy category: Not assigned. Risk Summary: Animal reproduction studies with this drug at doses up to 4 and 7 times the human dose, respectively, have revealed no harm to the fetus. The administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. Comments: -This drug has been used in cesarean section delivery but, because of its solubility and lack of protein binding, it readily and rapidly traverses the placenta.

See references

Methohexital Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Yes (in very small amounts) Comments: -Data indicate that no waiting period is required before resuming breastfeeding after a single dose of this drug. -When a combination of anesthetics is used, follow the recommendations for the most problematic medication.

See references

References for pregnancy information

  1. "Product Information. Brevital Sodium (methohexital)." Par Pharmaceutical Inc, Chestnut Ridge, NY.

References for breastfeeding information

  1. "Product Information. Brevital Sodium (methohexital)." Par Pharmaceutical Inc, Chestnut Ridge, NY.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.